Literature DB >> 90443

Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSF.

L Stendahl-Brodin, H Link, E Möller, E Norrby.   

Abstract

The HLA antigens B7 and Dw2 occurred at elevated frequencies in 105 multiple sclerosis (MS) patients (49 and 47%, respectively), compared to healthy controls (29 and 30%), especially in MS patients with oligoclonal CSF-IgG (51 and 50%), in cases with CSF-IgG index values above 1.5 (64 and 64%), and in those with the most malignant course of the disease (47 and 59%). Normal or only slightly elevated frequencies of B7 and Dw2 were found in MS patients without oligoclonal CSF IgG (35 and 29%), normal CSF-IgG index (43 and 39%), and the most benign course (42 and 37%). No correlation was found between the HLA type and measles virus antibody titers in serum or a measles virus antibody response within the CNS.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 90443     DOI: 10.1111/j.1600-0404.1979.tb02940.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  11 in total

1.  HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.

Authors:  A E Hensiek; S J Sawcer; R Feakes; J Deans; A Mander; E Akesson; R Roxburgh; F Coraddu; S Smith; D A S Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

2.  An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus.

Authors:  G C DeLuca; S V Ramagopalan; B M Herrera; D A Dyment; M R Lincoln; A Montpetit; M Pugliatti; M C N Barnardo; N J Risch; A D Sadovnick; M Chao; S Sotgiu; T J Hudson; G C Ebers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

3.  HLA and prognosis in multiple sclerosis.

Authors:  B Runmarker; T Martinsson; J Wahlström; O Andersen
Journal:  J Neurol       Date:  1994-05       Impact factor: 4.849

4.  Immunoglobulin G heavy chain (Gm) allotypes in multiple sclerosis.

Authors:  J P Pandey; J M Goust; J P Salier; H H Fudenberg
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

5.  HLA antigens in Italian multiple sclerosis patients.

Authors:  L La Mantia; M T Illeni; C Milanese; A Salmaggi; M Eoli; G Pellegris; A Nespolo
Journal:  Ital J Neurol Sci       Date:  1991-02

6.  B cells as a target of immune modulation.

Authors:  Kathleen Hawker
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

7.  HLA-antigens and the prognosis of multiple sclerosis.

Authors:  S Poser; G Ritter; H J Bauer; H Grosse-Wilde; E K Kuwert; N E Raun
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

8.  HLA antigens and progression of multiple sclerosis. Part II.

Authors:  L Dejaegher; M de Bruyere; P Ketelaer; H Carton
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

9.  Histocompatibility antigens in multiple sclerosis patients participating in a multicentre trial of azathioprine. British & Dutch Multiple Sclerosis Azathioprine Trial Group.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-03       Impact factor: 10.154

10.  Combined influences of Gm and HLA phenotypes upon multiple sclerosis susceptibility and severity.

Authors:  J P Salier; R Sesboüé; C Martin-Mondière; M Daveau; P Cesaro; B Cavelier; A Coquerel; L Legrand; J M Goust; J D Degos
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.